To include your compound in the COVID-19 Resource Center, submit it here.

Darinaparsin: Phase II started

Solasia began an open-label, Asian Phase II trial to evaluate 300 mg/m 2

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE